SGLT2 Inhibition Spotlight
Details & Video
This program offers participants downloadable slides and a program worksheet. View the PROGRAM MATERIALS tab for more information.
Overview & Objectives
A case-based discussion on SGLT2 inhibition across the spectrum of diabetes, kidney disease, and heart failure.
Following participation in this program, participants will be able to:
- Review the protection provided SGLT2 inhibitors along the clinical spectrum of diabetes and cardiorenal disease.
- Identify the role of earlier SGLT2 inhibition treatment in the at-risk patient with diabetes.
- Explore the potential for SGLT2 inhibitors to exert clinical benefits beyond diabetes in the management of heart failure.
|SGLT2 inhibitors across the diabetes and cardio-renal spectrum||Milan Gupta|
|The patient with high-risk diabetes||Sue Pederson|
|The patient with chronic kidney disease||Andrew Steele|
|The patient with heart failure||Milan Gupta|
|Practical management tips around SGLT2 inhibitor use||All|
|SGLT2 inhibitors across the diabetes and cardio-renal spectrum|
|The patient with high-risk diabetes|
|The patient with chronic kidney disease|
|The patient with heart failure|
|Practical management tips around SGLT2 inhibitor use|
Links & Resources
Download program handout/worksheet:
This program was developed by the Canadian Collaborative Research Network, a not-for-profit physician organization. A PDF copy of the slides from this program are available for CCRN members from the CCRN website. Click the link below to be directed to the Resource Library.